Screener
Royalty Pharma RPRX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Available for sale debt securities | 372,100 | 419,000 |
| Equity method investments | 261,973 | 289,968 |
| Goodwill | 923,535 | 924,634 |
| Other assets | 62,958 | 79,293 |
| Total assets | $19,819,771 | $19,620,780 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Distributions payable to non-controlling interests | $91,280 | $72,825 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's deferred tax assets and other non-current assets?
- Royalty Pharma (RPRX) reported deferred tax assets and other non-current assets of $62.96M in Q2 2026.
- How has Royalty Pharma's deferred tax assets and other non-current assets changed year-over-year?
- Royalty Pharma's deferred tax assets and other non-current assets decreased by 26.4% year-over-year, from $85.49M to $62.96M.
- What is the long-term trend for Royalty Pharma's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Royalty Pharma's deferred tax assets and other non-current assets has grown at a 51.3% compound annual growth rate (CAGR), from $10M to $79.29M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about Royalty Pharma's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude